理查德·戴利加入了我们的董事会在2015年2月至2014年10月，戴利先生曾担任阿斯利康美国糖尿病，在那里他领导了$ 1.2十亿，3000名员工的部门所有商业和医疗计划和目标，包括成功推出的总统的孤儿/罕见疾病的药物，Myalept，对脂肪代谢障碍。从2011年到2013年，戴利先生担任的联合创始人和合伙人Sagepath，该公司提供的制药行业外包商业服务的投资者。From 2008 to 2011, Mr. Daly was employed by Takeda N.A., the North American subsidiary of Takeda Pharmaceuticals, serving first as Vice President, Integration, leading a 6,500 person commercial/R&D merger between TAP Pharmaceuticals and Takeda N.A., then as Executive Vice President of Takeda N.A., with commercial responsibility for all businesses in the Americas. From 2006 to 2008, Mr. Daly served as the Vice President, Commercial Strategy for TAP Pharmaceuticals, a joint venture between Takeda Pharmaceuticals and Abbott Labs. In 1998, Mr. Daly was a founding member of the leadership team of Takeda Pharmaceuticals N.A., serving initially as the Senior Director of Marketing. Between 1998 and 2006, Mr. Daly took on roles of increasing responsibility culminating in his appointment as Senior Vice President, Marketing (2001-2006). Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.